Results 121 to 130 of about 23,251 (254)

Flow cytometric assessment of T‐cell receptor β‐chain constant region 1/2 skewing as a surrogate marker for clonality in human T‐cell leukaemia virus type‐1–infected cells

open access: yesBritish Journal of Haematology, EarlyView.
Summary Estimating T‐cell clonality within human T‐cell leukaemia virus type 1 (HTLV‐1)–infected cell populations may aid risk assessment and diagnosis of adult T‐cell leukaemia/lymphoma (ATL). However, direct assessment of HTLV‐1 integration‐site clonality requires genetic analyses that are costly and labour‐intensive.
Koji Jimbo   +10 more
wiley   +1 more source

Minimal residual disease-guided ibrutinib and venetoclax in patients with chronic lymphocytic leukaemia and complex karyotype. [PDF]

open access: yesBr J Haematol
Kislova M   +15 more
europepmc   +1 more source

Whole‐genome and transcriptome analysis in relapsed/refractory non‐Hodgkin lymphoma: Results from a multicentre precision oncology cohort

open access: yesBritish Journal of Haematology, EarlyView.
Summary Comprehensive genome and transcriptome profiling can inform the diagnosis, prognosis and management of relapsed/refractory (R/R) solid malignancies, yet its integration into clinical care has lagged despite strong biological rationale. We evaluated the clinical utility of whole genome and transcriptome analysis (WGTA) in 65 patients (37 ...
Kathleen Wee   +24 more
wiley   +1 more source

Complex karyotype and non‐BTK driver mutations associated with BTK inhibitor resistance in chronic lymphocytic leukaemia

open access: yesBritish Journal of Haematology, EarlyView.
This graphical abstract illustrates the genetic status in chronic lymphocytic leukaemia (CLL) patients with or without progression on Bruton tyrosine kinase (BTK) inhibitors. It highlights universal clonal evolution, where 100% of progressive disease cases acquired BTK or TP53 mutations.
Kiyomi Mashima   +20 more
wiley   +1 more source

CD20 antigen loss post‐venetoclax/anti‐CD20 therapy in chronic lymphocytic leukaemia: Frequency, characteristics and potential therapeutic implications

open access: yesBritish Journal of Haematology, EarlyView.
Summary Venetoclax plus anti‐CD20 monoclonal antibody (mAb) regimens have revolutionised treatment for chronic lymphocytic leukaemia (CLL); however, CD20 antigen loss is a potential consequence. Given emerging roles for re‐treatment with venetoclax plus anti‐CD20 mAb and CD20‐targeting bispecific antibodies in CLL, we retrospectively assessed the ...
Tamasine Stewart   +15 more
wiley   +1 more source

Leveraging venetoclax‐induced autophagy to enhance AUTAC‐mediated Mcl1 degradation and overcome resistance in acute myeloid leukaemia

open access: yes
British Journal of Haematology, EarlyView.
Ahmed M. Elshazly   +5 more
wiley   +1 more source

Long‐read nanopore sequencing: A rapid and highly accurate approach for IGHV gene analysis in chronic lymphocytic leukaemia

open access: yesBritish Journal of Haematology, EarlyView.
Summary The somatic hypermutation (SHM) status of the immunoglobulin heavy variable (IGHV) gene is a key prognostic and predictive biomarker in chronic lymphocytic leukaemia (CLL). Current methods, including Sanger sequencing and short‐read next‐generation sequencing, are accurate but have limitations in scalability and turnaround time.
Teresa del Peso Santos   +6 more
wiley   +1 more source

Trends and socio-economic disparities in chronic lymphocytic leukaemia 2014-2022: An England-wide cohort study from the UNCOVER group. [PDF]

open access: yesBr J Haematol
Erinfolami T   +18 more
europepmc   +1 more source

From infusion to pills in acute myeloid leukaemia: Reorganizing care beyond the infusion unit

open access: yes
British Journal of Haematology, EarlyView.
Fortunato Morabito   +11 more
wiley   +1 more source

Home - About - Disclaimer - Privacy